OSMAN ERGANİŞ, HASAN HÜSEYİN HADİMLİ, ZAFER SAYIN, ASLI SAKMANOĞLU, YASEMİN PINARKARA, ÖZGÜR ÖZDEMİR

Efficacy of experimental inactivated and live Rhodococcus equivaccines for thoroughbred Arabian mares in mice

The aim of this study was to determine the efficacy of inactive Rhodococcus equi vaccine candidates included that bacterin+aluminum hydroxide (Al(OH)3), bacterin+VapA+(Al(OH)3), bacterin+Montanide IMS 3012 (IMS), bacterin+VapA+IMS, and live vaccine using mice as a model. The efficacy of vaccine was evaluated according to clinical findings, humoral and cellular immunity (levels of INF-g and IL-4), and results of microbiological culture from internal organs in dead or sacrificed mice. Inactive R. Equi vaccines were subcutaneously administered to mice three times at 15-day intervals and live vaccine was intraperitoneally injected once. Fifteen days after the last vaccination, aerosol challenges were carried out with the pathogenic R. Equi VapA+K2002 strain in all groups. Two mice were sacrificed from each challenge groups on days 1, 3, 5, and 7. The antibody titers of vaccinated mice were found to be significantly higher than those of the controls. The largest number of INF-g positive samples were detected in the bacterin+VapA+IMS and bacterin+IMS groups. IL-4 positivity was determined only in live vaccine groups. The lowest reisolation rate of R. Equi from internal organs was observed in the bacterin+VapA+IMS group. It was concluded that R. Equi vaccines, and especially bacterin+VapA+IMS, are useful to protect mice against R. Equi infection.

Anahtar Kelimeler:

Rhodococcus equi, vaccine, mice model, VapA, Montanide IMS 3012, Al(OH)3

Efficacy of experimental inactivated and live Rhodococcus equivaccines for thoroughbred Arabian mares in mice

Keywords:

Rhodococcus equi, vaccine, mice model, VapA, Montanide IMS 3012, Al(OH)3,

PDF

___

Meijer WG, Prescott JF. Rhodococcus equi. Vet Res 2004; 35: 383–396.
Pei Y, Nicholson V, Woods C, Prescott CF. Immunization by intrabronchial administration to 1-week-old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103+. Vet Microbiol 2007; 125: 100–110.
Butler JE. Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals. OIE Revue Scientifique et Technique 1998; 17: 43–70.
Güler L, Gündüz K, Erganiş O, Durmaz M, Ok U, Gülcü Y. Rhodococcus equi pneumonia in foals: immunoprophylaxis, molecular and sero diagnostic studies. In: VI. National Congress of Veterinary Microbiology; Elazığ, Turkey; 2004 (in Turkish).
Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25: 3752–3762.
Taouji S, Nomura I, Giguere S, Tomomitsu S, Kakuda T, Ganne V, Takai S. Immunogenicity of synthetic peptides representing linear B-cell epitopes of vapA of Rhodococcus equi. Vaccine 2004; 22: 1114–1123.
Cauchard J, Sevine C, Ballet JJ, Taouji S. Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine. Vet Microbiol 2004; 104: 73–81.
Erganis O, Sayin Z, Hadimli HH, Sakmanoglu A, Pinarkara Y, Ozdemir O, Maden M. The effectiveness of anti-R. equi hyperimmune plasma against R. equi challenge in thoroughbred Arabian foals of mares vaccinated with R. equi vaccine. Sci World J 2014; 2014: 480732.
Phumoonna T, Barton MD, Vanniasinkam T, Heuzenroeder MW. Chimeric vap A/gro EL2DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice. Vaccine 2008; 26: 2457–2465.
Takai S, Kawazu S, Tsubaki S. Enzyme-linked immunosorbent assay for diagnosis of Corynebacterium (Rhodococcus) equi infection in foal. Am J Vet Res 1985; 46: 2166–2170.
Prescott JF, Patterson MC, Nicholson VM, Morein B, Yager JA. Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice. Vet Microbiol 1997; 56: 213–225.
Whitehead AE, Parreira VR, Hewson J, Watson JL, Prescott JF. Development of a live, attenuated, potential vaccine strain of Rhodococcus equi expressing vapA and the virR operon and virulence assesment in the mouse. Vet Immun Immunpathol 2012; 145: 479–484.
Vanniasinkam T, Barton MD, Heuzenroeder MW. Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model. Int J Med Microbiol 2005; 294: 437–445.
Hines SA, Kanaly ST, Byrne BA. Immunity to Rhodococcus equi. Vet Microbiol 1997; 56: 177–185.
Oliveira AF, Soares SG, Roque-Barreira MC. Mice vaccination with VapA: challenge with Rhodococcus equi is followed by production of TH1 cytokines. Vet Immun Immunpathol 2009; 128: 241–242.
Oliveira AF, Luciana PR, Cardoso SA, Soares SG, Roque- Barreira MC. Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection. PLoS One 2010; 5: e8644.
Haghighi HR, Prescott JF. Assessment in mice of vapA–DNA vaccination against Rhodococcus equi infection. Vet Immunol Immunopathol 2005; 104: 215–225.
Lopez AM, Townsand HG, Allen AL, Hondalus MK. Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen. Vaccine 2008; 26: 998–1009.
Gonzalez-Iglesias P, Scortti M, MacArthur I, Hapeshi A, Rodriguez H, Prescott JF, Vazquez-Boland JA. Mouse lung infection model to assess Rhodococcus equi virulence and vaccine protection. Vet Microbiol 2014; 172: 256–264.